1

Sequential copper catalyzed alkyne-azide and thiolene click reactions for the multiple functionalization of fullerene hexaadducts

Jean-François Nierengarten, Julien Iehl

Laboratoire de Chimie des Matériaux Moléculaires, Université de Strasbourg et CNRS (UMR 7509), Ecole Européenne de Chimie, Polymères et Matériaux (ECPM), 25 rue Becquerel, 67087 Strasbourg Cedex 2 (France). E-mail: nierengarten@chimie.u-strasbg.fr

2

General. Reagents and solvents were purchased as reagent grade and used without further purification. Compound 7^1 was prepared according to a previously reported procedure. All reactions were performed in standard glassware under an inert Ar or N_2 atmosphere. Evaporation and concentration were done at water aspirator pressure and drying in vacuo at 10^{-2} Torr. Column chromatography: silica gel 60 (230-400 mesh, 0.040-0.063 mm) was purchased from E. Merck. Thin Layer Chromatography (TLC) was performed on glass sheets coated with silica gel 60 F_{254} purchased from E. Merck, visualization by UV light. IR spectra (cm⁻¹) were measured on an ATI Mattson Genesis Series FTIR instrument. NMR spectra were recorded on a Bruker AC 300 or AC 400 with solvent peaks as reference. MALDI-TOF-mass spectra were carried out on a Bruker BIFLEX matrix-assisted laser desorption time-of-flight mass spectrometer.

Preparation of compound 1

Compound 13. DCC (14.24 g, 69.69 mmol) was added to a solution of **12** (6 g, 69.69 mmol), 1,4-butanediol (9.32 mL, 104.54 mmol), HOBt (0.94 g, 6.97 mmol) and DMAP (1.70 g, 13.94 mmol) in CH₂Cl₂ (300 mL) at 0 °C under argon. The mixture was stirred for 48 h, filtered through a celite pad and concentrated. Column chromatography (SiO₂, CH₂Cl₂) yielded **13** (5.6 g, 51%) as a colorless oil. 1 H NMR (CDCl₃, 300 MHz): 6.06 (dq, J = 4 and 1.5 Hz, 1H), 5.51 (dq, J = 4 and 1.5 Hz, 1H), 4.14 (t, J = 6 Hz, 2H), 3.63 (t, J = 6 Hz, 2H), 2.25 (s, 1H), 1.90 (m, 3H); 13 C NMR (CDCl₃, 75 MHz): 167.5, 136.3, 125.3, 64.4, 62.1, 29.0, 25.0, 18.2.

¹ J. Iehl, R. Pereira de Freitas, B. Delavaux-Nicot and J.-F. Nierengarten, *Chem. Commun.* 2008, 2450.

Compound 1. Malonyl dichloride (0.62 mL, 6.32 mmol) was added to a solution of **13** (2 g, 12.64 mmol) and pyridine (1.02 mL, 12.64 mmol) in CH₂Cl₂ (100 mL) at 0°C. After 1 h, the mixture was allowed to warm up to room temperature, then stirred for 18 h, filtered, and evaporated. Column chromatography (SiO₂, CH₂Cl₂/AcOEt 9:1) gave **1** (2.17 g, 89%) as a pale yellow oil. IR (neat): 1740 (C=O), 1714 (C=O), 1637 (C=C); ¹H NMR (CDCl₃, 300 MHz): 6.05 (m, 2H), 5.51 (m, 2H), 4.14 (m, 8H), 3.34 (s, 2H), 1.89 (m, 6H), 1.71 (m, 8H); ¹³C NMR (CDCl₃, 75 MHz): 167.2, 166.3, 136.2, 125.3, 64.9, 63.9, 41.3, 25.1(x2), 18.1.

Preparation of compound 2

Compound 2. CBr₄ (12.64 g, 38.13 mmol), **1** (1.46 g, 3.81 mmol), and DBU (1.14 mL, 7.63 mmol) were added successively to a solution of C_{60} (0.27 g, 0.375 mmol) in ODCB (80 mL). The mixture was stirred for 72 h and evaporated. Column chromatography (SiO₂, CH₂Cl₂/AcOEt 8:2) gave **2** (0.47 g, 41%) as an orange glassy product. IR (neat): 1742 (C=O), 1713 (C=O), 1636 (C=C); UV/Vis (CH₂Cl₂): 245 (93500), 269 (68600), 283 (70000), 318 (sh, 42600), 338 (sh, 31100); ¹H NMR (CDCl₃, 300 MHz): 6.03 (m, 12H), 5.50 (m, 12H), 4.26 (t, J = 6 Hz, 24H), 4.10 (t, J = 6 Hz, 24H), 1.87 (m, 36H), 1.73 (m, 48H); ¹³C NMR (CDCl₃, 75 MHz): 167.0, 163.4, 145.6, 140.9, 136.1, 125.3, 68.9, 66.2, 63.6, 45.1, 25.1(x2), 18.1; MALDI-TOF-MS: 3015 (M⁺, calcd. for $C_{174}H_{156}O_{48}$: 3015.12).

Preparation of compounds 4a-c

General procedure. AIBN (3 equiv.) was added to a mixture of **2** (1 equiv.) and the appropriate thiol (20 equiv.) in carefully degassed benzene. The resulting mixture was stirred for 1 h at 80°C. The mixture was then diluted with a small amount of CH₂Cl₂ and the product precipitated by addition of cyclohexane and filtered. The product was then purified as outlined in the following text.

Compound 4a. This compound was prepared from **2** (158 mg, 0.052 mmol), **3a** (80 mg, 1.04 mmol), AIBN (26 mg, 0.16 mmol) in benzene (5 mL). Column chromatography (SiO₂, CH₂Cl₂ containing 0.5% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave **4a** (104 mg, 51%) as a red glassy product. IR (neat): 1728 (C=O); UV/Vis (CH₂Cl₂): 245 (115200), 269 (80200), 282 (77400), 320 (sh, 44500), 338 (sh, 33900); 1 H NMR (CDCl₃, 300 MHz): 4.30 (m, 24H), 4.12 (m, 24H), 2.81 (m, 12H), 2.67 (m, 12H), 2.57 (m, 12H), 2.49 (t, J = 7 Hz, 24H), 1.77 (m, 48H), 1.58 (q, J = 7 Hz, 24H), 1.25 (d, J = 7 Hz, 36H), 0.97 (t, J = 7 Hz, 36H); 13 C NMR (CDCl₃, 75 MHz): 175.0, 174.3, 163.5 (several peaks), 145.9 (several peaks), 140.9 (several peaks), 69.3 (several peaks), 64.2 (several peaks), 63.6 (several peaks), 45.2 (several peaks), 40.2, 32.7, 31.8, 25.0 (several peaks), 22.8, 16.8, 13.3 (several peaks); MALDI-TOF-MS: 3929 (M⁺, calcd. for C₂₁₀H₂₅₂O₄₈S₁₂: 3929.0).

Compound 4b. This compound was prepared from **2** (133 mg, 0.04 mmol), **3b** (154 mg, 0.88 mmol), AIBN (22 mg, 0.13 mmol) in benzene (3 mL). Column chromatography (SiO₂, CH₂Cl₂ containing 1% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave **4b** (79 mg, 35%) as a red glassy product. IR (neat): 1728 (C=O); UV/Vis (CH₂Cl₂): 246 (116200), 269 (88100), 283 (84300), 325 (sh, 48500), 337 (sh, 39600); 1 H NMR (CDCl₃, 300 MHz): 4.29 (m, 24H), 4.12 (m, 24H), 2.77 (m, 12H), 2.68 (m, 12H), 2.56 (m, 12H), 2.49 (t, J = 7 Hz, 24H), 1.76 (m, 48H), 1.53 (m, 24H), 1.24 (m, 216H), 0.86 (t, J = 7 Hz, 36H); 13 C NMR (CDCl₃, 75 MHz): 176.2 (several peaks), 175.0, 174.4, 163.6 (several peaks), 145.9 (several peaks), 140.9 (several peaks), 69.0 (several peaks), 64.3 (several peaks), 63.7 (several peaks), 45.2 (several peaks), 40.2, 32.7, 31.8, 29.8, 29.6, 29.5, 29.3, 29.25, 29.2, 28.8, 25.0 (several peaks), 16.9, 14.0; MALDI-TOF-MS: 5107 (M⁺, calcd. for C₂₉₄H₄₂₀O₄₈S₁₂: 5107.26).

Compound 4c. This compound was prepared from **2** (200 mg, 0.06 mmol), **3c** (120 mg, 1.33 mmol), AIBN (33 mg, 0.2 mmol) in benzene (5 mL). Column chromatography (SiO₂, CH₂Cl₂ containing 1% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave **4c** (140 mg, 52%) as a red glassy product. IR (neat): 1726 (C=O); UV/Vis (CH₂Cl₂): 245 (91200), 269 (69300), 283 (65100), 322 (sh, 38700), 339 (sh, 29400); ¹H NMR (CDCl₃, 300 MHz): 4.28 (m, 24H), 4.11 (m, 24H), 2.79 (m, 12H), 2.59 (m, 24H), 1.75 (m, 48H), 1.28 (m, 108H), 1.24 (m, 36H); ¹³C NMR (CDCl₃, 75 MHz): ¹³C NMR (CDCl₃, 75 MHz): 176.3 (several peaks), 175.0, 163.4 (several peaks), 146.0 (several peaks), 140.8 (several peaks), 68.9 (several peaks), 66.4 (several peaks), 63.6 (several peaks), 45.2 (several peaks), 40.3, 31.6, 30.8, 30.7, 25.1 (several peaks), 17.1; MALDI-TOF-MS: 4097 (M⁺, calcd. for C₂₂₂H₂₇₆O₄₈S₁₂: 4097.32).

Preparation of compound 5.

Compound 5. Malonyl dichloride (0.92 mL, 9.48 mmol) was added to a solution of **13** (1.5 g, 9.48 mmol), **14** (1.48 g, 9.48 mmol) and pyridine (1.53 mL, 18.96 mmol) in CH₂Cl₂ (150 mL) at 0°C. After 1 h, the mixture was allowed to warm up to room temperature, then stirred for 16 h, filtered, and evaporated. Column chromatography (SiO₂, CH₂Cl₂/Hexane 9:1) gave **5** (1.35 g, 37%) as a colorless oil. IR (neat): 2175 (C≡C), 1742 (C=O), 1713 (C=O), 1636 (C=C); 1 H NMR (CDCl₃, 300 MHz): 6.07 (dq, J = 4 and 1.5 Hz, 1H), 5.53 (dq, J = 4 and 1.5 Hz, 1H), 4.21 (t, J = 6 Hz, 2H), 4.16 (m, 4H), 3.35 (s, 2H), 2.29 (t, J = 6 Hz, 2H), 1.91 (m, 3H), 1.83 (t, J = 6 Hz, 2H), 1.74 (m, 4H), 0.11 (s, 9H); 13 C NMR (CDCl₃, 75 MHz): 167.2, 166.4, 166.3, 136.3, 125.3, 105.3, 85.4, 64.9, 64.1, 63.9, 41.4, 27.5, 25.2, 25.1, 18.2, 16.4, 0.0.

Preparation of compound 6.

Compound 6. DBU (1.27 mL, 8.49 mmol) was added to a stirred solution of C_{60} (2.45 g, 3.39 mmol), I_2 (1.3 g, 5.09 mmol) and **5** (1.3 g, 3.39 mmol) in toluene (2.45 L) at room temperature. The resulting solution was stirred for 12 h, then filtered through a short plug of SiO₂ (CH₂Cl₂) and evaporated. Column chromatography (SiO₂, CH₂Cl₂/Hexane 6/4) gave **5** (1.87 g, 50%) as a dark red glassy product. IR (neat): 2174 (C≡C), 1742 (C=O), 1713 (C=O), 1636 (C=C); UV/Vis (CH₂Cl₂): 257 (123000), 227 (95400), 327 (36300), 360 (sh, 11000), 393 (3700), 414 (sh, 1700), 426 (1900); 1 H NMR (CDCl₃, 300 MHz): 6.12 (m, 1H), 5.57 (m, 1H), 4.59 (t, J = 6 Hz, 2H), 4.55 (t, J = 6 Hz, 2H), 4.23 (t, J = 6 Hz, 2H), 2.43 (t, J = 6 Hz, 2H), 2.05 (q, J = 6 Hz, 2H), 1.95 (m, 3H), 1.90 (m, 4H), 0.16 (s, 9H); 13 C NMR (CDCl₃, 75

MHz): 167.3, 163.5(x2), 145.3, 145.2(x2), 145.1(x2), 144.9, 144.7, 144.6, 143.9, 143.1, 143.0(x2), 142.2, 141.9, 141.8, 141.0, 139.0(x2), 136.3, 125.6, 105.0, 86.0, 71.5, 66.8, 65.8, 63.9, 52.1, 27.6, 25.4, 25.3, 18.3, 16.6, 0.1; MALDI-TOF-MS: 1101 (M^+ , calcd. for $C_{79}H_{28}O_6Si$: 1101.17).

Preparation of compound 8.

Compound 8. CBr₄ (15.05 g, 45.4 mmol), **7** (1.22 g, 4.54 mmol), and DBU (1.36 mL, 9.08 mmol) were added successively to a solution of **6** (0.5 g, 0.45 mmol) in ODCB (90 mL). The mixture was stirred for 72 h and evaporated. Column chromatography (SiO₂, CH₂Cl₂) gave **8** (0.62 g, 57%) as an orange glassy product. IR (neat): 2174 (C≡C), 2094 (N₃), 1742 (C=O), 1713 (C=O), 1636 (C=C); 1 H NMR (CDCl₃, 300 MHz): 6.08 (m, 1H), 5.55 (m, 1H), 4.35 (m, 24H), 4.16 (t, J = 6 Hz, 2H), 3.38 (t, J = 6 Hz, 20H), 2.30 (t, J = 6 Hz, 2H), 1.95 (m, 27H), 1.81 (q, J = 6 Hz, 2H), 0.12 (m, 9H); 13 C NMR (CDCl₃, 75 MHz): 166.7, 163.0 (several peaks), 161.5, 145.3 (several peaks), 140.6 (several peaks), 135.8, 125.0, 104.7, 85.2, 68.6, 66.1, 65.2, 63.7, 63.4 (several peaks), 62.6, 59.1, 47.9, 47.4 (several peaks), 47.1, 44.8, 31.1, 30.4, 27.5 (several peaks), 24.8, 24.7, 17.8, 16.0, -0.4.

Preparation of compound 9.

Compound 9. A mixture of **8** (0.62 mg, 0.25 mmol), phenylacetylene (315 mg, 3.08 mmol), CuSO₄.5H₂O (4 mg, 0.025 mmol) and sodium ascorbate (15 mg, 0.077 mmol) in CH₂Cl₂/H₂O (1:1, 10 mL) was vigorously stirred at rt. After 24 h, the organic layer was diluted with CH₂Cl₂, washed with water, dried (MgSO₄) and concentrated. Column chromatography (SiO₂, CH₂Cl₂ containing 2% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave **9** (588 mg, 66%) as an orange glassy product. IR (neat): 2173 (C≡C), 1740 (C=O), 1713 (C=O), 1636 (C=C); UV/Vis (CH₂Cl₂): 246 (234800), 270 (117400), 283 (67500), 319 (sh, 36100), 340 (sh, 25200);): 8.00-7.75 (m, 30H), 7.45-7.25 (m, 30H), 6.12 (m, 1H), 5.58 (m, 1H), 4.47 (m, 20H), 4.39 (m, 24H), 4.16 (t, J = 6 Hz, 2H), 2.34 (m, 22H), 1.96 (m, 3H), 1.90 (m, 4H), 1.78 (m, 2H), 0.12 (m, 9H); ¹³C NMR (CDCl₃, 75 MHz): 167.0, 163.2 (several peaks), 147.6, 145.6 (several peaks), 141.0 (several peaks), 136.0, 130.3, 128.6, 127.9, 125.4, 120.0, 104.8, 85.6, 69.1, 69.0, 68.9, 66.5, 65.6, 63.6 (several peaks), 46.6 (several peaks), 45.1, 29.0 (several peaks), 27.2, 24.9, 24.8, 18.1, 16.2, -0.1; MALDI-TOF-MS: 3464 (M⁺, calcd. for C₂₀₄H₁₄₈N₃₀O₂₆Si: 3463.69).

Preparation of compound 10.

Compound 10. A 1 M solution of TBAF in THF (0.12 mL, 0.12 mmol) was added to a mixture of 9 (200 mg, 0.057 mmol), benzyl azide (23 mg, 0.17 mmol), CuSO₄.5H₂O (3.4 mg, 0.0057 mmol) and sodium ascorbate (3.4 mg, 0.017 mmol) in CH₂Cl₂/H₂O (1:1, 3 mL). The resulting mixture was vigorously stirred at rt. After 12 h, the organic layer was diluted with CH₂Cl₂, washed with water, dried (MgSO₄) and concentrated. Column chromatography (SiO₂, CH₂Cl₂ containing 3% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave **10** (178 mg, 87 %) as an orange glassy product. IR (neat): 1739 (C=O), 1713 (C=O), 1636 (C=C); UV/Vis (CH₂Cl₂): 246 (213600), 265 (115200), 286 (40300), 318 (sh, 21900), 337 (sh, 15800); ¹H NMR (CDCl₃, 300 MHz): 8.00-7.75 (m, 33H), 7.45-7.25 (m, 33H), 6.04 (m, 1H), 5.51 (m, 1H), 5.44 (s, 2H), 4.41 (m, 20H), 4.33 (m, 26H), 4.08 (t, J = 6Hz, 2H), 2.68 (m, 2H), 2.30 (m, 20H), 1.89 (m, 3H), 1.69 (m, 4H); ¹³C NMR (CDCl₃, 75 MHz): 167.1, 163.3 (several peaks), 161.8, 147.7, 146.5, 145.7 (several peaks), 141.0 (several peaks), 136.0, 134.8, 130.3, 128.9, 128.7, 128.0, 125.5, 120.9, 120.3, 120.0, 69.2, 69.0, 66.6, 66.3 (several peaks), 63.8, 63.6, 63.1, 53.8, 46.7 (several peaks), 46.3, 45.3, 29.5, 29.1 (several peaks), 28.8, 27.9, 25.0, 24.9, 21.9, 18.2; MALDI-TOF-MS: 3524 (M⁺, calcd. for $C_{208}H_{146}N_{33}O_{26}$: 3523.65).

Preparation of compounds 11a-c.

General procedure. AIBN (3 equiv.) was added to a mixture of 10 (1 equiv.) and the appropriate thiol (20 equiv.) in carefully degassed THF. The resulting mixture was refluxed for 1 h. The mixture was then diluted with a small amount of CH₂Cl₂ and the product precipitated by addition of cyclohexane and filtered. The product was then purified as outlined in the following text.

Compound 11a. This compound was prepared from **10** (100 mg, 0.003 mmol), **3b** (42 mg, 0.56 mmol), AIBN (14 mg, 0.084 mmol) in THF (2 mL). Column chromatography (SiO₂, CH₂Cl₂ containing 2% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave **11a** (72 mg, 70%) as a red glassy product. IR (neat): 1740 (C=O); UV/Vis (CH₂Cl₂): 247 (196100), 265 (110100), 286 (46600), 318 (sh, 26400), 335 (sh, 20100); ¹H NMR (CDCl₃, 300 MHz): 8.00-7.75 (m, 33H), 7.45-7.25 (m, 33H), 5.44 (s, 2H), 4.43 (m, 20H), 4.33 (m, 26H), 4.05 (m, 2H), 2.72 (m, 3H), 2.34 (m, 24H), 1.64 (m, 6H), 1.20 (m, 3H), 0.94 (m, 3H); ¹³C NMR (CDCl₃, 75 MHz): 163.3 (several peaks), 161.9, 147.8, 146.6, 145.8 (several peaks), 141.1 (several peaks), 134.8, 130.4, 128.9, 128.8, 128.5, 128.1, 127.9, 125.6, 121.0, 120.3, 120.0, 69.1 (several peaks), 66.5 (several peaks), 63.8, 63.6, 63.1, 53.8, 46.7 (several peaks), 46.4, 45.4, 40.2, 32.6, 31.8, 29.2 (several peaks), 25.0 (several

peaks), 22.0, 16.8, 13.3 (several peaks); MALDI-TOF-MS: 3600 (M^+ , calcd. for $C_{211}H_{155}N_{33}O_{26}S$: 3600.82).

Compound 11b. This compound was prepared from **10** (54 mg, 0.015 mmol), **3b** (53 mg, 0.3 mmol), AIBN (8 mg, 0.045 mmol) in THF (1 mL). Column chromatography (SiO₂, CH₂Cl₂ containing 2% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave **11b** (51 mg, 91%) as a red glassy product. IR (neat): 1739 (C=O); UV/Vis (CH₂Cl₂): 246 (204800), 256 (170200), 284 (63600), 318 (sh, 37400), 339 (sh, 27800); ¹H NMR (CDCl₃, 300 MHz): 8.00-7.75 (m, 33H), 7.45-7.25 (m, 33H), 5.44 (s, 2H), 4.43 (m, 20H), 4.35 (m, 26H), 4.07 (m, 2H), 2.68 (m, 3H), 2.31 (m, 24H), 1.71 (m, 6H), 1.23 (m, 17H), 0.86 (m, 3H); ¹³C NMR (CDCl₃, 75 MHz): 163.4 (several peaks), 147.8 (several peaks), 145.8 (several peaks), 141.1 (several peaks), 134.8, 130.4, 128.9, 128.8, 128.5, 128.1, 127.9, 125.6, 121.0, 120.1, 120.0, 69.1 (several peaks), 66.4 (several peaks), 63.8, 63.7, 63.1, 53.8, 46.8 (several peaks), 46.4, 45.4, 40.2, 32.6, 31.8, 29.2, 28.0, 26.7, 25.0 (several peaks), 22.6, 22.0, 20.6, 16.8, 14.1 (several peaks); MALDI-TOF-MS: 3698 (M⁺, calcd. for C₂₁₈H₁₆₉N₃₃O₂₆S: 3699.01).

Compound 11c. This compound was prepared from 10 (100 mg, 0.003 mmol), 3c (51 mg, 0.56 mmol), AIBN (14 mg, 0.084 mmol) in THF (2 mL). Column chromatography (SiO₂, CH₂Cl₂ containing 3% of methanol) followed by gel permeation chromatography (Biobeads SX-1, CH₂Cl₂) gave 11c (64 mg, 62%) as a red glassy product. IR (neat): 1740 (C=O); UV/Vis (CH₂Cl₂): 246 (188400), 263 (120300), 285 (60200), 320 (sh, 36600), 338 (sh, 28700); ¹H NMR (CDCl₃, 300 MHz): 8.00-7.75 (m, 33H), 7.45-7.25 (m, 33H), 5.43 (s, 2H), 4.41 (m, 20H), 4.34 (m, 26H), 4.07 (m, 2H), 2.68 (m, 3H), 2.30 (m, 22H), 1.70 (m, 4H), 1.26 (m, 12H); ¹³C NMR (CDCl₃, 75 MHz): 163.4 (several peaks), 147.8, 146.6, 145.8 (several peaks), 141.1 (several peaks), 134.8, 130.4, 128.9, 128.8, 128.5, 128.1, 127.9, 125.6, 121.0, 120.1, 120.0, 69.1 (several peaks), 66.4 (several peaks), 63.7 (several peaks), 53.9, 46.7 (several peaks), 45.4, 40.2, 32.3, 29.2 (several peaks), 28.0, 25.0 (several peaks), 22.6, 22.0, 20.6; MALDI-TOF-MS: 3614 (M⁺, calcd. for C₂₁₂H₁₅₇N₃₃O₂₆S: 3614.84).

- Fig. S1. ¹H NMR spectra (300 MHz, CDCl₃) of 1 (top), 2 (middle) and 4a (bottom).
- **Fig. S2.** ¹³C NMR spectra (75 MHz, CDCl₃) of **2** (top) and **4b** (bottom); unambiguous assignment was achieved with the help of the corresponding DEPT spectra. As the thiol-ene click reaction generates an asymetric center, compounds **4b** is indeed obtained as a mixture of diastereoisomers. As a result, its ¹³C NMR spectrum is quite broad.
- **Fig. S3**. Partial view of the ¹H NMR spectra (300 MHz, CDCl₃) of **9** (top), **10** (middle) and **11a** (bottom) highlighting the appearance of typical benzylic CH₂ resonance when going from **9** to **10** as well as the disappearance of the vinylic signals when going from **10** to **11a**.
- **Fig. S4**. ¹³C NMR spectrum (75 MHz, CDCl₃) of **9**; unambiguous assignment was achieved with the help of the corresponding DEPT spectrum.
- **Fig. S5**. ¹³C NMR spectrum (75 MHz, CDCl₃) of **10**; unambiguous assignment was achieved with the help of the corresponding DEPT spectrum.
- **Fig. S6**. ¹³C NMR spectrum (100 MHz, CDCl₃) of **11c**; unambiguous assignment was achieved with the help of the corresponding DEPT spectrum.
- **Fig. S7**. MALDI-TOF mass spectrum of compound **9** showing the expected molecular ion peak at 3464 (calcd. for $C_{204}H_{148}N_{30}O_{26}Si$: 3463.69); characteristic fragments are also highlighted.
- **Fig. S8**. MALDI-TOF mass spectrum of compound **10** showing the expected molecular ion peak at 3524 (calcd. for $C_{208}H_{146}N_{33}O_{26}$: 3523.65); characteristic fragments are also highlighted.
- **Fig. S9**. MALDI-TOF mass spectrum of compound **11b** showing the expected molecular ion peak at 3698 (calcd. for $C_{218}H_{169}N_{33}O_{26}S$: 3699.01); characteristic fragments are also highlighted.

Fig. S1.




Fig. S2.




Fig. S3.




Fig. S4.




Fig. S5.




Fig S6.




Fig. S7.




Fig. S8.




Fig. S9.

